Home > Clinical Trials
Check All Search

Saved trials

COMPLETED
NCT02612649
Special Drug Use Surveillance of Irribow in Female Patients
793 Enrollment(s)
34 Study location(s)
OBSERVATIONAL (None)
Diarrhea-predominant Irritable Bowel Syndrome
COMPLETED
NCT01892371
Quizartinib With Azacitidine or Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
73 Enrollment(s)
1 Study location(s)
INTERVENTIONAL (PHASE1|||PHASE2)
FLT3 Gene Mutation Negative


FLT3 Internal Tandem Duplication Positive


Recurrent Acute Myeloid Leukemia


Recurrent Chronic Myelomonocytic Leukemia


Recurrent Myelodysplastic Syndrome


Refractory Acute Myeloid Leukemia


Refractory Chronic Myelomonocytic Leukemia


Refractory Myelodysplastic Syndrome
NOT_YET_RECRUITING
NCT06630130
Perioperative Therapies in Locally Advanced Unresectable Gastric Cancer
50 Enrollment(s)
1 Study location(s)
INTERVENTIONAL (PHASE2)
Stomach Neoplasms
COMPLETED
NCT05103332
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2)
672 Enrollment(s)
110 Study location(s)
INTERVENTIONAL (PHASE2)
Hypertension
RECRUITING
NCT04493138
Azacitidine and Quizartinib for the Treatment of Myelodysplastic Syndrome or Myelodysplastic/Myeloproliferative Neoplasm With FLT3 or CBL Mutations
58 Enrollment(s)
1 Study location(s)
INTERVENTIONAL (PHASE1|||PHASE2)
Chronic Myelomonocytic Leukemia


Myelodysplastic Syndrome


Myeloproliferative Neoplasm


Recurrent Chronic Myelomonocytic Leukemia


Recurrent Myelodysplastic Syndrome


Recurrent Myeloproliferative Neoplasm
NOT_YET_RECRUITING
NCT06585969
A Randomised Trial Comparing Trastuzumab Deruxtecan to CDK4/6 Inhibitors in Non-luminal A, ER-positive/HER2-low Metastatic Breast Cancer
504 Enrollment(s)
1 Study location(s)
INTERVENTIONAL (PHASE3)
Metastatic Breast Cancer


ER-positive Breast Cancer


Luminal B


Her2 Enriched


Basal Like
ACTIVE_NOT_RECRUITING
NCT05954143
Trial of BDC-1001 +/- Pertuzumab in Subjects With HER2-Positive Metastatic Breast Cancer
11 Enrollment(s)
4 Study location(s)
INTERVENTIONAL (PHASE2)
Metastatic Breast Cancer


HER2-positive Breast Cancer
ACTIVE_NOT_RECRUITING
NCT04622319
A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05)
1,600 Enrollment(s)
482 Study location(s)
INTERVENTIONAL (PHASE3)
HER2-Positive Primary Breast Cancer


Residual Invasive Breast Cancer